QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Filgrastim Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Filgrastim: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which observation is most consistent with an expected pharmacodynamic effect rather than, by itself, a rare serious syndrome?

Bone pain during rapid marrow expansion Hypotension with haemoconcentration and oedema Shoulder-tip pain with falling haemoglobin Persistent fever with aortic-wall inflammation on imaging

Question 2 of 10 Which statement best describes the relationship between G-CSF receptor activation and mature neutrophil function?

G-CSF receptor activation affects only progenitor-cell proliferation and has no effect on mature neutrophils It can enhance mature neutrophil functional activity, including phagocytic and microbicidal functions, in addition to effects on precursors It directly supplies antibodies to mature neutrophils It suppresses neutrophil trafficking to peripheral tissues in all contexts

Question 3 of 10 Which presentation should prompt consideration of filgrastim-associated aortitis?

Persistent fever, abdominal or back pain and raised inflammatory markers Transient bone pain immediately after injection with normal inflammatory markers Isolated mild thrombocytopenia after chemotherapy A single elevated ANC without symptoms

Question 4 of 10 Why should spontaneous reports be stratified by indication and exposure pattern when comparing filgrastim safety signals?

Because donor, oncology and chronic-neutropenia populations have identical exposure and background risks Because duration, disease biology, concomitant therapy, exposure denominators and reporting behaviour differ substantially across populations Because stratification removes the need for case-level medical review Because only the indication determines product identity

Question 5 of 10 Which conclusion is most scientifically defensible when a patient with severe congenital neutropenia develops clonal abnormalities after prolonged filgrastim treatment?

The temporal sequence proves filgrastim caused the transformation Filgrastim cannot be relevant because it is a supportive medicine The finding requires analysis of disease subtype, genotype, treatment exposure, dose requirement and clonal data because competing causes are interrelated The event should be classified only as an expected laboratory abnormality

Question 6 of 10 Why is a rising filgrastim dose requirement in severe chronic neutropenia clinically informative even before a case is coded as lack of efficacy?

It may indicate changing disease biology or response and therefore warrants longitudinal assessment It proves the patient is non-adherent It demonstrates that the product has become pegylated It has no relevance if the ANC is measured at least once

Question 7 of 10 Which case-management response is most appropriate when a patient receiving filgrastim reports new left upper abdominal pain?

Reassure the patient that abdominal pain is an expected minor effect and await the next routine count Promptly assess for splenic complications, including haemodynamic status, haemoglobin, imaging and mobilisation or dose history Stop all pharmacovigilance follow-up because the symptom is nonspecific Interpret the symptom solely as evidence of chemotherapy resistance

Question 8 of 10 Which statement best captures the therapeutic objective of filgrastim in chemotherapy-supported patients?

To produce sustained leukocytosis regardless of clinical context To eliminate the need for antimicrobial assessment when fever occurs To reduce the depth or duration of clinically consequential neutropenia or support neutrophil recovery To treat the underlying malignancy by directly killing malignant cells

Question 9 of 10 Why should an undifferentiated report of 'rash' sometimes be clinically refined before coding and signal review?

All rashes caused by filgrastim have the same clinical significance Specific diagnoses such as cutaneous small-vessel vasculitis or Sweet syndrome may carry different significance and require different assessment Rash terminology is never relevant to pharmacovigilance Refinement is needed only to determine the product's market share

Question 10 of 10 Why does a diagnosis of severe chronic neutropenia subtype matter when evaluating long-term filgrastim safety?

All chronic neutropenia subtypes have identical natural histories and transformation risks Congenital, cyclic, autoimmune and idiopathic disorders differ in disease biology and baseline risks, affecting interpretation of outcomes The subtype determines only the injection device and not the benefit–risk assessment Subtype information is relevant only for calculating the initial dose

QPPV.com

Professional Knowledge Assessment: Filgrastim Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings